Research Reports | Market Assessment
March 2022

Market Events and Forecast | Immunology | US/EU5 | 2021

In 2019, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this therapy area totaled approximately $3.5 billion. Throughout the 2019-2029 forecast period, increasing numbers of branded biologics in the immunology space are set to lose patent protection, and biosimilars will launch and reduce branded biologics’ patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports